Number of the records: 1
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
Title Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial / M. E. Gore ... [et al.] Another responsib. Gore, Martin (Author) Griffin, C. L. (Author) Hancock, B. (Author) Patel, P. M. (Author) Pyle, L. (Author) Aitchison, M. (Author) James, N. (Author) Oliver, R. T. D. (Author) Mardiak, Jozef (Author) Hussain, T. (Author) Sylvester, R. (Author) Parmar, M. K. (Author) Royston, P. (Author) Mulders, P. F. (Author) Translated title Interferón alfa-2a proti kombinovanej liečbe s interferónom alfa-2a, interleukínom-2 a fluorouracilom u pacientov s neliečeným metastastázujúcim karcinómom obličiek (MRC RE04/EORTC GU 30012): otvorená randomizovaná štúdia Note Lancet. 2010 Feb. 20, 375(9715): 641-8 Document source Onkológia. -- ISSN 1336-8176. -- Roč. 6, č. 1 (2011), s. 57 Call number C 3069 MeSH Subject karcinóm renálnych buniek - farmakoterapia metastázy nádorové farmakoterapia kombinovaná interferón alfa - použitie terapeutické interleukín-2 fluorouracil prežívanie bez choroby Form, Genre abstrakt v angličtine Language English Country Slovakia Database ARTICLES 
article
Number of the records: 1